NVCR
NovoCure Limited NASDAQ$16.62
Mkt Cap $1.9B
52w Low $9.82
66.4% of range
52w High $20.06
50d MA $12.05
200d MA $12.56
P/E (TTM)
-13.6x
EV/EBITDA
-13.7x
P/B
5.4x
Debt/Equity
0.8x
ROE
-40.0%
P/FCF
-19.0x
RSI (14)
—
ATR (14)
—
Beta
0.82
50d MA
$12.05
200d MA
$12.56
Avg Volume
1.9M
About
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothe…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | -0.51 | -0.62 | -21.0% | 11.93 | +12.0% | +27.5% | +39.3% | — | — | — | — | — |
| Feb 26, 2026 | BMO | -0.41 | -0.22 | +46.3% | 14.99 | -11.6% | -8.3% | -8.8% | -9.8% | -11.3% | -10.5% | -30.9% | — |
| Oct 30, 2025 | BMO | -0.42 | -0.33 | +21.4% | 13.48 | +0.0% | -4.9% | -5.0% | -9.3% | -11.0% | -13.9% | -13.4% | — |
| Jul 24, 2025 | BMO | -0.39 | -0.36 | +7.7% | 16.51 | -0.1% | -24.0% | -27.1% | -29.5% | -31.1% | -33.6% | -29.1% | — |
| Apr 24, 2025 | BMO | -0.47 | -0.31 | +34.0% | 17.77 | +6.6% | +4.4% | +4.1% | +3.0% | +2.9% | +2.1% | +7.9% | — |
| Feb 27, 2025 | BMO | -0.34 | -0.61 | -79.4% | 21.96 | -8.4% | -12.4% | -13.2% | -16.2% | -17.2% | -12.8% | -18.9% | — |
| Oct 30, 2024 | BMO | -0.34 | -0.28 | +17.6% | 16.89 | -0.7% | +0.6% | -10.1% | -4.2% | -1.8% | -1.6% | +18.7% | — |
| Jul 25, 2024 | BMO | -0.40 | -0.31 | +22.5% | 18.79 | +0.0% | -0.7% | +1.2% | +10.7% | +24.3% | +21.2% | -3.4% | — |
| May 2, 2024 | BMO | -0.43 | -0.36 | +16.3% | 12.74 | +5.1% | +11.4% | +16.0% | +22.1% | +21.9% | +25.8% | +87.5% | — |
| Feb 22, 2024 | BMO | -0.53 | -0.45 | +15.1% | 15.62 | +8.7% | -2.4% | -2.6% | -4.6% | +4.4% | +2.6% | -15.5% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $15.21 | $15.48 | +1.8% | +9.3% | — | — | — | — |
| Apr 16 | Wedbush | Maintains | Neutral → Neutral | — | $12.17 | $12.24 | +0.6% | +3.7% | +5.4% | +4.1% | +0.5% | +7.0% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.99 | $13.25 | -11.6% | -8.3% | -8.8% | -9.8% | -11.3% | -10.5% |
| Feb 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.50 | $14.40 | +37.1% | +19.3% | +4.7% | +6.0% | +8.6% | +8.5% |
| Jan 15 | Wedbush | Maintains | Neutral → Neutral | — | $13.77 | $13.79 | +0.1% | +0.2% | -0.9% | -5.4% | -1.5% | +3.1% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.18 | $13.86 | -2.3% | -3.7% | -2.9% | -2.7% | -3.8% | -8.2% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.48 | $13.48 | +0.0% | -4.9% | -5.0% | -9.3% | -11.0% | -13.9% |
| Oct 27 | JP Morgan | Maintains | Neutral → Neutral | — | $13.75 | $13.75 | +0.0% | -1.2% | -2.8% | -2.0% | -6.8% | -6.8% |
| Jul 25 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $12.54 | $12.73 | +1.5% | -4.0% | -7.2% | -9.3% | -12.5% | -7.7% |
| Jun 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.10 | $17.19 | +0.5% | +5.3% | +4.1% | +4.6% | +4.6% | +3.6% |
Recent Filings
8-K
NovoCure Limited -- 8-K Filing
NovoCure's strong early-year performance across its Tumor Treating Fields commercial and clinical programs positions the company favorably for continued growth in its oncology treatment portfolio.
Apr 30
8-K · 5.02
!!! Very High
NovoCure Limited -- 8-K 5.02: Executive Change
NovoCure's appointment of an executive officer lacks finalized compensation details, creating uncertainty about leadership costs and potential shareholder dilution from equity incentives.
Apr 24
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Novocure's Chief Innovation Officer assumes additional Chief Medical Officer duties, signaling either internal talent confidence or potential cost-cutting that could strain leadership capacity during critical product development phases.
Apr 9
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
NovoCure's PANOVA-4 trial met its primary endpoint with statistically significant disease control improvements, potentially supporting label expansion and driving revenue growth for this cancer treatment platform.
Mar 26
8-K
NovoCure Limited -- 8-K Filing
NovoCure achieved record patient treatment volumes with its Tumor Treating Fields therapy in 2025, signaling strong commercial momentum and market adoption for the cancer treatment technology.
Feb 26
8-K · 7.01
! Medium
NovoCure Limited -- 8-K 7.01: Regulation FD Disclosure
NovoCure's Medicare billing privileges were revoked retroactively to December 2025 due to an administrative re-validation procedural lapse, not performance failure, creating significant revenue uncertainty for the company's core products.
Feb 24
8-K · 7.01
! Medium
NovoCure Limited -- 8-K 7.01: Regulation FD Disclosure
NovoCure's Optune Pax received FDA approval for locally advanced pancreatic cancer treatment alongside chemotherapy, potentially expanding the company's addressable market and revenue opportunities.
Feb 11
8-K · 7.01
! Medium
NovoCure Limited -- 8-K 7.01: Regulation FD Disclosure
NovoCure's Medicare billing privileges were revoked December 17, 2025 due to an administrative re-validation procedural issue, potentially threatening U.S. revenue until the company resolves the CMS compliance matter.
Feb 5
Data updated apr 26, 2026 4:14pm
· Source: massive.com